Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$63.40
-$1.91(-4.25%)
At close: 4:00 PM EDT
$63.40
-$1.91(-4.25%)
Day’s Range― - ―
52-Week Range$7.26 - $240.00
Previous CloseN/A
Volume106.73K
Average Volume (3M)57.24K
Market Cap
$171.49M
Enterprise Value$42.66
Total Cash (Recent Filing)$96.30M
Total Debt (Recent Filing)$7.67M
Price to Earnings (P/E)―
Beta-10.28
Next Earnings
Nov 16, 2026EPS Estimate
-5.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-40.87
Shares Outstanding2,874,013
10 Day Avg. Volume77,329
30 Day Avg. Volume57,244
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$153.17Price Target Upside141.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-26.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery modest debt relative to equity limits interest and refinancing pressure, preserving financial flexibility for clinical development. This is a durable balance-sheet advantage, although it does not eliminate the need to fund ongoing operating losses.
Experienced Rare-disease LeadershipA chief medical officer with rare-disease development, pharmacovigilance, medical-affairs, and launch experience can strengthen trial execution and regulatory planning. That expertise may improve the company’s ability to advance programs in its specialized therapeutic niche.
Improving Cash-flow TrendThe improvement in free-cash-flow growth suggests cash consumption may be moderating relative to the prior period. While cash flow remains negative, sustained improvement could extend funding runway and support more disciplined clinical investment over the next several months.
Bears Say
No Current Product RevenueThe absence of recurring product revenue leaves the company dependent on financing, partnerships, or future development success. Continued losses indicate that the business has not yet demonstrated commercial traction or a self-sustaining operating model.
Persistent Operating Cash BurnSubstantial ongoing cash consumption requires continued access to capital or collaboration funding to maintain clinical programs. This creates dilution, financing, and execution risk, particularly because current cash generation does not fund research and development internally.
Inconsistent Revenue And Value ErosionThe return to zero revenue after earlier reported revenue highlights limited commercial consistency. Deeply negative returns on equity also show that ongoing losses are eroding shareholder value, reinforcing the company’s dependence on successful pipeline execution.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $7.26 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $171.49M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 73 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Aug 12, 2026. The company reported -$6.68 earnings per share for the quarter, missing the consensus estimate of -$5.79 by -$0.89.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -5.86.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 2,874,013 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$6.68 in its last earnings report, missing expectations of -$5.79. Following the earnings report the stock price went up 1.422%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$153.17 (141.59% Upside)
$153.17 (141.59% Upside)
Blogger Sentiment
Neutral
SPRB Sentiment 50%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
608.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
371.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
SPRB Stock 12 Month Forecast
Average Price Target
$153.17
▲(141.59% Upside)
Technical Analysis
Ownership Overview
1.04% Insiders
0.99% Mutual Funds
37.19% Other Institutional Investors
52.08% Public Companies and
Individual Investors